NCT02504580View on ClinicalTrials.gov

A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

PHASE2CompletedINTERVENTIONAL
Enrollment

463

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

April 30, 2017

Conditions
Postoperative Pain
Interventions
DRUG

HTX-011

HTX-011 (bupivacaine/meloxicam) by injection.

DRUG

Placebo

Saline placebo by injection.

DRUG

HTX-002

HTX-002, by injection or instillation (pooled).

DRUG

Bupivacaine HCI (Marcaine)

Bupivacaine HCI (Marcaine) by injection.

DRUG

HTX-011A

HTX-011A (bupivacaine/meloxicam) by injection.

DRUG

HTX-011B

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

DRUG

HTX-009

HTX-009 by injection and instillation (combination).

Trial Locations (3)

77004

Houston

77027

Houston

92801

Anaheim

Sponsors

Lead Sponsor

Heron Therapeutics
All Listed Sponsors
lead

Heron Therapeutics

INDUSTRY